Skip to main content
Accelsius Achieves Industry-Leading Thermal Milestones for Next-Generation AI Computing – Read more
Innventure - Creating companies to transform tomorrow.
Companies
Companies
PureCycle
AeroFlexx
Accelsius
Refinity
Our Companies
Press Release
Climb Channel Solutions Launches Global Partnership with Accelsius LLC
About
Our Team
Meet Innventure's world-class team of seasoned executives and entrepreneurs across industries.
Connect
What We Do
Optimize R&D investments with our unique technology commercialization approach.
Learn
How We Work
See how we systematically approach evaluating, commercializing, and advancing technologies.
Explore
Careers
Learn more about career opportunities at Innventure. Help transform technologies into companies.
Apply
News & Media
News & Media
News
Events
Insights
Featured Insight
How Scientific Thinking Can Revolutionize Business Strategy
ContactInvestors
Innventure - Creating companies to transform tomorrow.
Menu
Companies
Back
Companies
All Companies
PureCycle
AeroFlexx
Accelsius
Refinity
About
Back
About
Our Team
What We Do
How We Work
Careers
News & Media
Back
News & Media
News
Events
Insights
ContactInvestors
News & Media

How to Mitigate the Risks of Innovation

Category

Media Coverage

Company

Innventure

Date

April 12, 2023

Press Contact

press@innventure.com

Share

There is massive potential profit to be made in exploiting truly innovative, disruptive technology. But changing the world necessarily entails risks. Perhaps the most fundamental of these is getting the market to adopt the new innovation, as most people are generally reluctant to change what they are doing in favour of an alternate solution.

The first way entrepreneurs should mitigate risk, therefore, is to create business models that compel the market in their favour by delivering economically attractive solutions. Toward this end, startups should be founded on immediate, compelling, and quantitative value propositions (or “iCQVPs”).

Almost 25 years ago, my team and I created an automated microscope that systematically searches through anything you could put on a slide (such as blood), looking for the proverbial needle in a haystack. Our task was to automate and dramatically improve pathologists’ ability to find a few cancer cells among a matrix of millions of normal cells.

In short, we were able to reduce the diagnostic process from hours to minutes with nearly 100 per cent identification – a fundamental step change in cellular diagnostics. Since earlier and more reliable detection leads to earlier treatment, this technology promised better patient outcomes. As an article in Science points out, “57 per cent of people with lung cancer survive their disease for five years or more when diagnosed at stage I compared with only three per cent of those diagnosed at stage IV.” Early detection also generates tremendous savings for the health-care system.

When introducing this disruptive solution into the market, we planned to sell instruments that would materially reduce the life-cycle cost of patient care. We quantified this benefit to insurance companies and demonstrated that by buying a machine for a few hundred thousand dollars, they could save many millions of dollars in a few short years.

We quickly learned, however, that insurance companies would not pay for such a system upfront. They didn’t want to outlay capital when the relevant patients could be in someone else’s insurance pool by the time the savings would be realized.

That roadblock led us to rethink our business model. We needed to provide an immediate benefit to the payor – in this case, the insurance companies – without the risk.

As such, we redesigned our value proposition by providing the instrument to the payors for free. In return, we asked for a revenue share for any new incremental dollars the instrument could produce. Every time the instrument ran a reimbursable test, we would receive one-third of the revenue, and the client would receive two-thirds.

With this new value proposition, the benefits to the market were immediate: insurance companies received money for every test run on the instrument from the start. This was compelling because insurance companies could adopt this new approach with nearly zero risk since it required no upfront investment. Finally, it was quantitative – if reimbursement for a given test was $3,000, the client received $2,000. Previously, insurance companies had outsourced this work to reference laboratories, so our machine constituted a new source of revenue.

This fundamental change in the business model reduced risk and generated profit for our clients, leading to their rapid adoption of the invention. It also actually created more value for us than our original plan of selling the instruments would have.

I have designed business models with the iCQVP methodology ever since learning that lesson early in my career. Many entrepreneurs balk at the idea of taking on truly disruptive enterprises.

Still, in my experience, it’s just as hard (or as easy) to make a billion dollars as it is to make a million. Part of the secret is creating business plans around iCQVPs.

News

You May Also Like

All NEws
5.2.2025

Climb Channel Solutions Launches Global Partnership with Accelsius LLC

Accelsius
4.30.2025

Innventure to Present at Upcoming Innovation Conferences

Innventure
4.10.2025

Accelsius Achieves Industry-Leading Thermal Milestones for Next-Generation AI Computing

Accelsius
Media Coverage

Finding Disruptive Technologies for Company Creation

This is some text inside of a div block.
Media Coverage

Sectors With The Most Opportunity To Scale A Business In 2023

This is some text inside of a div block.
Media Coverage

Innventure: Founding, Funding, & Operating Influential Ventures

This is some text inside of a div block.
For Multinational Corporations
innovate@innventure.com
For Investor Relations
investorrelations@innventure.com
For Press Inquiries
press@innventure.com
Learn
Our TeamWhat We DoHow We WorkCareers
Explore
All CompaniesPureCycleAeroFlexxAccelsiusRefinity
Engage
NewsInsightsEventsContactInvestors
Innventure.
© 2023. All Rights Reserved.
Privacy PolicyTerms of Use

Your Privacy is important to us

Customize your cookie preferences or click “Accept All” to agree to the storing of cookies on your device. View our Privacy Policy for more information.
Preferences
Accept
Deny
Privacy Preference Center

Below we list the different types of cookies that we use on the Site.  The specific cookies that we use, and the categories to which they belong, are available in the consent manager. To the extent any personal information is collected through cookies, our Privacy Policy applies and complements this Policy.

Always Allow Cookies
Close
Manage Consent Preferences
Required cookies enable you to navigate the Site and to use its services and features.  Without these absolutely necessary cookies, we may not be able to provide the Site or certain services or features, and the Site will not perform as smoothly for you as we would like it to.

These cookies are used to deliver advertising that is more relevant to you and your interests. They may also be used to limit the number of times you see an advertisement and measure the effectiveness of advertising campaigns. Advertising networks usually place them with the website operator’s permission.

These cookies allow us to analyze your use of the Site to evaluate and improve our performance, for example, by providing us information about how our site is used.

Reject AllConfirm My Choices
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.